Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

Indivior CEO Sentenced to Prison Following Park Doctrine Plea

By Josh Levy on October 25, 2020
Email this postTweet this postLike this postShare this post on LinkedIn

On October 22, 2020, the former CEO of Indivior PLC, Shaun Thaxter, was sentenced to six months of imprisonment for his conviction on one misdemeanor count of misbranding in violation of the Federal Food, Drug, and Cosmetic Act (“FDCA”).

Thaxter’s conviction, which arises from Indivior’s marketing of its opioid-based product Suboxone Film, is particularly significant because it is based on the rarely used “responsible corporate officer” doctrine (also known as the “Park doctrine”). Under the Park doctrine, Thaxter’s conviction is based on his role as a responsible executive who failed to prevent or correct Indivior’s illegal acts in violating the FDCA, instead of his direct involvement in those illegal acts.

While most criminal statutes require the government to prove some level of intent, the FDCA does not impose an intent requirement for misdemeanors.  Thus, Thaxter could be held criminally liable for negligently failing to prevent an offense at Indivior even if he did not have direct knowledge of the alleged misconduct. Notably, the government did not allege that Thaxter played a personal role in sending false and misleading data to the Massachusetts government (the allegations resulting in Thaxter’s conviction).  Instead, Thaxter’s alleged involvement with Medicaid consisted only of business development efforts and encouraging his marketing staff to win preferred drug status for Suboxone.

However, the government alleged that Indivior developed misleading marketing materials and encouraged providers to prescribe Suboxone in situations where it was not clinically warranted, and because Thaxter was responsible for overseeing those efforts, he could indirectly be held liable under the FDCA for these acts.

Related links are available at: DOJ Press Release; Thaxter Criminal Information; Law 360 Coverage; Ropes & Gray LLP Alert.

Photo of Josh Levy Josh Levy

Joshua Levy is co-chair of the global Litigation and Enforcement practice group at Ropes & Gray LLP. He focuses on white collar defense and related complex civil litigation, particularly in the health care, pharmaceutical, medical device and Health IT industries. In 2019, Joshua…

Joshua Levy is co-chair of the global Litigation and Enforcement practice group at Ropes & Gray LLP. He focuses on white collar defense and related complex civil litigation, particularly in the health care, pharmaceutical, medical device and Health IT industries. In 2019, Joshua was lead counsel for one of the parents charged in the college admissions scandal. In 2018 and 2019, Joshua represented both Pfizer and Alexion in securing favorable False Claims Act settlements involving novel kickback theories relating to Patient Assistance Programs. In 2017, Joshua led a team that secured a $40 million criminal and civil global resolution with DOJ, FDA, OIG and the SEC, which included criminal misbranding and HIPAA charges. In 2016, Mr. Levy secured a complete acquittal after a three-week trial in federal court of a real estate developer and he was named as one of the Lawyers of the Year by Massachusetts Lawyers Weekly. In 2016, Joshua also led teams that secured the first DOJ declination under the FCPA Pilot Program and won a significant False Claims Act case dismissal in the First Circuit Court of Appeals.

Read more about Josh LevyEmail
Show more Show less
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Life Sciences Securities Litigation
  • Organization:
    Ropes & Gray

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo